Outcomes in COVID-19 nitazoxanide studies
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI] Treatment Control Cadegiani 88%
0.12 [0.01-2.52]
death
0/357
2/137
Elalfy 87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT​1 ​
Silva (SB RCT) 26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
death
1/184
0/195
Tau​2 ​ = 1.35; I​2 ​ = 77.4%
Early treatment 49%
0.51 [0.13-1.95]
10/820
46/594
49% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 67%
0.33 [0.07-1.50]
2/25
6/25
67% improvement All studies 55%
0.45 [0.15-1.35]
12/845
52/619
55% improvement 6 nitazoxanide COVID-19 studies c19nitazoxanide.com Dec 3, 2021
​1 ​ CT: study uses combined treatment Tau​2 ​ = 1.03; I​2 ​ = 71.7%; Z = 1.42 Effect extraction pre-specified
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani 88%
0.12 [0.01-2.52]
0/357
2/137
Improvement, RR [CI] Treatment Control Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
1/184
0/195
Tau​2 ​ = 2.67; I​2 ​ = 51.4%
Early treatment 41%
0.59 [0.02-13.8]
1/541
2/332
41% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
2/25
6/25
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 67%
0.33 [0.07-1.50]
2/25
6/25
67% improvement All studies 60%
0.40 [0.10-1.58]
3/566
8/357
60% improvement 3 nitazoxanide COVID-19 mortality results c19nitazoxanide.com Dec 3, 2021
Tau​2 ​ = 0.17; I​2 ​ = 9.3%; Z = 1.31
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Cadegiani 97%
0.03 [0.00-0.51]
0/357
9/137
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Early treatment 97%
0.03 [0.00-0.51]
0/357
9/137
97% improvement Blum (DB RCT) 62%
0.38 [0.11-1.25]
3/25
8/25
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 62%
0.38 [0.11-1.25]
3/25
8/25
62% improvement All studies 85%
0.15 [0.01-1.62]
3/382
17/162
85% improvement 2 nitazoxanide COVID-19 mechanical ventilation results c19nitazoxanide.com Dec 3, 2021
Tau​2 ​ = 1.96; I​2 ​ = 61.3%; Z = 1.56
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
2/194
0/198
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Early treatment -404%
5.04 [0.24-104]
2/194
0/198
-404% improvement All studies -404%
5.04 [0.24-104]
2/194
0/198
-404% improvement 1 nitazoxanide COVID-19 ICU result c19nitazoxanide.com Dec 3, 2021
Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 1.05
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -2%
1.02 [0.30-3.47]
hosp.
5/194
5/198
Improvement, RR [CI] Treatment Control Cadegiani 99%
0.01 [0.00-0.17]
hosp.
0/357
27/137
Rossignol (DB RCT) 79%
0.21 [0.02-1.80]
hosp.
1/184
5/195
Tau​2 ​ = 3.68; I​2 ​ = 78.4%
Early treatment 83%
0.17 [0.01-2.00]
6/735
37/530
83% improvement Blum (DB RCT) 56%
0.44 [0.22-0.89]
hosp. time
25 (n)
25 (n)
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 56%
0.44 [0.22-0.89]
0/25
0/25
56% improvement All studies 71%
0.29 [0.08-1.06]
6/760
37/555
71% improvement 4 nitazoxanide COVID-19 hospitalization results c19nitazoxanide.com Dec 3, 2021
Tau​2 ​ = 1.06; I​2 ​ = 67.6%; Z = 1.88
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI] Treatment Control Cadegiani 88%
0.12 [0.01-2.52]
death
0/357
2/137
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
death
1/184
0/195
Tau​2 ​ = 1.71; I​2 ​ = 40.9%
Early treatment -21%
1.21 [0.12-12.3]
3/735
2/530
-21% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 67%
0.33 [0.07-1.50]
2/25
6/25
67% improvement All studies 31%
0.69 [0.15-3.29]
5/760
8/555
31% improvement 4 nitazoxanide COVID-19 serious outcomes c19nitazoxanide.com Dec 3, 2021
Tau​2 ​ = 0.88; I​2 ​ = 33.9%; Z = 0.46
Effect extraction pre-specified
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -16%
1.16 [0.84-1.59]
no recov.
59/194
52/198
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Early treatment -16%
1.16 [0.84-1.59]
59/194
52/198
-16% improvement All studies -16%
1.16 [0.84-1.59]
59/194
52/198
-16% improvement 1 nitazoxanide COVID-19 recovery result c19nitazoxanide.com Dec 3, 2021
Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.91
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) 12%
0.88 [0.80-0.96]
viral+
194 (n)
198 (n)
Improvement, RR [CI] Treatment Control Elalfy 87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT​1 ​
Silva (SB RCT) 26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Tau​2 ​ = 0.78; I​2 ​ = 92.8%
Early treatment 54%
0.46 [0.16-1.30]
7/279
44/262
54% improvement Blum (DB RCT) 90%
0.10 [0.01-1.78]
viral+
0/23
4/19
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 90%
0.10 [0.01-1.78]
0/23
4/19
90% improvement All studies 60%
0.40 [0.15-1.09]
7/302
48/281
60% improvement 4 nitazoxanide COVID-19 viral clearance results c19nitazoxanide.com Dec 3, 2021
​1 ​ CT: study uses combined treatment Tau​2 ​ = 0.79; I​2 ​ = 89.9%; Z = 1.79 Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI] Treatment Control Silva (SB RCT) 26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
death
1/184
0/195
Tau​2 ​ = 0.09; I​2 ​ = 6.3%
Early treatment 8%
0.92 [0.41-2.08]
3/401
0/406
8% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 67%
0.33 [0.07-1.50]
2/25
6/25
67% improvement All studies 25%
0.75 [0.36-1.55]
5/426
6/431
25% improvement 4 nitazoxanide COVID-19 Randomized Controlled Trials c19nitazoxanide.com Dec 3, 2021
Tau​2 ​ = 0.09; I​2 ​ = 11.3%; Z = 0.78
Effect extraction pre-specified
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
1/184
0/195
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Early treatment -206%
3.06 [0.13-74.6]
1/184
0/195
-206% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
2/25
6/25
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 67%
0.33 [0.07-1.50]
2/25
6/25
67% improvement All studies 37%
0.63 [0.09-4.54]
3/209
6/220
37% improvement 2 nitazoxanide COVID-19 RCT mortality results c19nitazoxanide.com Dec 3, 2021
Tau​2 ​ = 0.84; I​2 ​ = 34.0%; Z = 0.45
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI] Treatment Control Cadegiani 88%
0.12 [0.01-2.52]
death
0/357
2/137
Elalfy 87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT​1 ​
Tau​2 ​ = 2.14; I​2 ​ = 62.4%
Early treatment 68%
0.32 [0.04-2.58]
9/613
46/386
68% improvement Blum (DB RCT) 67%
0.33 [0.07-1.50]
death
2/25
6/25
Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0%
Late treatment 67%
0.33 [0.07-1.50]
2/25
6/25
67% improvement All studies 73%
0.27 [0.08-0.94]
11/638
52/411
73% improvement 4 nitazoxanide COVID-19 peer reviewed trials c19nitazoxanide.com Dec 3, 2021
​1 ​ CT: study uses combined treatment Tau​2 ​ = 0.76; I​2 ​ = 51.1%; Z = 2.06 Effect extraction pre-specified
Favors nitazoxanide
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Rocco (RCT) -404%
5.04 [0.24-104]
ICU
2/194
0/198
Improvement, RR [CI] Treatment Control Rocco (RCT) -2%
1.02 [0.30-3.47]
hosp.
5/194
5/198
Rocco (RCT) -16%
1.16 [0.84-1.59]
no recov.
59/194
52/198
Rocco (RCT) 12%
0.88 [0.80-0.96]
viral+
194 (n)
198 (n)
Rocco (RCT) 14%
0.86 [0.77-0.96]
viral+
136/194
162/198
Cadegiani 88%
0.12 [0.01-2.52]
death
0/357
2/137
Cadegiani 97%
0.03 [0.00-0.51]
ventilation
0/357
9/137
Cadegiani 99%
0.01 [0.00-0.17]
hosp.
0/357
27/137
Elalfy 87%
0.13 [0.06-0.27]
viral+
7/62
44/51
CT​1 ​
Elalfy 58%
0.42 [0.31-0.56]
viral+
26/62
51/51
CT​1 ​
Silva (SB RCT) 26%
0.74 [0.38-1.41]
viral+
23 (n)
13 (n)
Silva (SB RCT) 38%
0.62 [0.39-0.97]
viral+
12/23
11/13
Rossignol (DB RCT) -206%
3.06 [0.13-74.6]
death
1/184
0/195
Rossignol (DB RCT) 79%
0.21 [0.02-1.80]
hosp.
1/184
5/195
Rossignol (DB RCT) 85%
0.15 [0.02-1.22]
severe case
1/184
7/195
Rossignol (DB RCT) 84%
0.16 [0.02-1.29]
severe case
1/112
7/126
Blum (DB RCT) 67%
0.33 [0.07-1.50]
death
2/25
6/25
Blum (DB RCT) 62%
0.38 [0.11-1.25]
ventilation
3/25
8/25
Blum (DB RCT) 56%
0.44 [0.22-0.89]
hosp. time
25 (n)
25 (n)
Blum (DB RCT) 90%
0.10 [0.01-1.78]
viral+
0/23
4/19
nitazoxanide COVID-19 outcomes c19nitazoxanide.com Dec 3, 2021
Favors nitazoxanide
Favors control
Please send us corrections, updates, or comments.
Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC .
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
